Navigation Links
Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan

MOUNTAIN VIEW, Calif., April 26, 2012 /PRNewswire/ -- Glaucoma is the second leading cause of blindness in the United States, presenting the glaucoma pharmaceuticals market with a significant opportunity to fulfill unmet medical needs. Being an adult disease, the patient pool for glaucoma will expand as the population ages.

New analysis from Frost & Sullivan's ( Analysis of the United States Glaucoma Pharmaceuticals Market research finds that the market earned revenues of approximately $2.19 billion in 2010 and estimates this to reach $2.25 billion in 2016.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at, with your full name, company name, job title, telephone number, company email address, company Web site, city, state and country.

Considering almost 50 percent of the patient population is under-diagnosed and underserved with available pharmacotherapy options, pharmaceuticals that offer effective therapies, improved drug delivery, and higher disease awareness through patient education will be immensely successful.

Additionally, patients suffering from glaucoma, whether they are aware of the disease or not, need therapies better than the numerous pharmacotherapy options available currently.

"The underserved population of patients is not achieving therapy goals and demonstrates poor patient compliance with daily eye drops," said Frost & Sullivan Industry Analyst Debbie Toscano. "There is considerable need for more effective therapies that go beyond targeting intraocular pressure to preserve optic nerve function, as well as for innovations in delivery to improve patient compliance and clinical outcomes."

So far, the availability of a number of low-cost generic medications, including a generic version of the gold-standard prostaglandin analog (PA), Xalatan, may reduce the attractiveness of this market to potential participants. As glaucoma requires life-long therapy, there is a huge demand for low-cost therapeutic options, which slows down innovation in the market. The increasing economic pressures are also expected to compel payers and prescribers to encourage the use of generics.

However, there is a substantial need for innovation in drug delivery and alternatives to daily eye drops. For example, many patients, particularly the elderly, have difficulty in self-administering them. Eye drops also involve other challenges such as high frequency of administration, wastage of drops, and inability to last for the duration of prescription, leading to non-compliance and under-treatment.

Innovative pharmaceutical and biotech companies seeking to tap into this market have to offer improved therapies exhibiting novel mechanisms and/or delivery methods. Novelty in mechanisms that address the underlying causes of glaucoma and provide additional clinical benefit such as neuroprotection is vital to improve patient outcomes and prevent blindness.

"The heterogeneous nature of the pathophysiology of glaucoma and the variable patient response to therapy drive the need for multiple effective therapeutic choices," said Toscano.  "Currently, PAs dominate the market with 59.8 percent of the total share due to their superior efficacy, tolerability and convenience profiles. The introduction of this class to the market has significantly raised the bar for new entrants."

Analysis of the United States Glaucoma Pharmaceuticals Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: U.S. Retinal Therapeutics Market, European Ophthalmic Pharmaceuticals Market, U.S. Glaucoma Pharmaceuticals Market, and 2010 U.S. Ophthalmologists' Assessment of Eye Care Medication Brands. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit

Analysis of the United States Glaucoma Pharmaceuticals Market

Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003

SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Colorectal Cancer Screening Coverage to Drive US Gastrointestinal Endoscopy Device Market to Almost $2.2 Billion by 2014
2. St. Jude Medical and Hospitals in Ohio and Kentucky to Pay Almost $4 Million to Federal Government to Resolve Fraud Allegations
3. Global Atrial Fibrillation Device Market to Grow by Almost 10% Through 2013
4. Global Spinal Nonfusion Market to Reach Almost $2 Billion By 2013, According to Millennium Research Group
5. CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year
6. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
7. Entering its Prime: Southeast Michigan ePrescribing Initiative, One of the Nations Longest Running ePrescribing Programs, Increases Enrollment by 33 Percent; Kicks off Seventh Year
8. Huntzinger Management Group, Inc., (HMG) Further Invests in Healthcare Industrys "90 Percent"
9. Volcano Reports 14 Percent Increase in Fourth Quarter Revenues; Medical Segment Revenues Grow 20 Percent
10. Mesa Labs Reports 58 Percent Increase in Third Quarter Net Income
11. Amgens Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33
Post Your Comments:
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):